相似文献
1
Structure-activity relationship studies to probe the phosphoprotein binding site on the carboxy terminal domains of the breast cancer susceptibility gene 1.
J Med Chem. 2011 Jun 23;54(12):4264-8. doi: 10.1021/jm1016413. Epub 2011 May 26.
2
Structural characterization of BRCT-tetrapeptide binding interactions.
Biochem Biophys Res Commun. 2010 Mar 5;393(2):207-10. doi: 10.1016/j.bbrc.2010.01.098. Epub 2010 Feb 1.
3
Phosphopeptide interactions with BRCA1 BRCT domains: More than just a motif.
Prog Biophys Mol Biol. 2015 Mar;117(2-3):143-148. doi: 10.1016/j.pbiomolbio.2015.02.003. Epub 2015 Feb 17.
4
Comparison of BRCT domains of BRCA1 and 53BP1: a biophysical analysis.
Protein Sci. 2004 Mar;13(3):617-25. doi: 10.1110/ps.03461404.
5
Kinetic analysis of interaction of BRCA1 tandem breast cancer c-terminal domains with phosphorylated peptides reveals two binding conformations.
Biochemistry. 2008 Sep 16;47(37):9866-79. doi: 10.1021/bi702247d. Epub 2008 Aug 22.
6
"Similarity trap" in protein-protein interactions could be carcinogenic: simulations of p53 core domain complexed with 53BP1 and BRCA1 BRCT domains.
Structure. 2006 Dec;14(12):1811-21. doi: 10.1016/j.str.2006.10.009.
7
β-Hairpins as peptidomimetics of human phosphoprotein-binding domains.
Org Biomol Chem. 2019 Apr 17;17(16):3996-4004. doi: 10.1039/c9ob00564a.
8
The BRCT domain is a phospho-protein binding domain.
Science. 2003 Oct 24;302(5645):639-42. doi: 10.1126/science.1088753.
9
Cancer predisposing mutations in BRCT domains.
IUBMB Life. 2011 Jul;63(7):503-12. doi: 10.1002/iub.472.
10
Computational and experimental studies of the interaction between phospho-peptides and the C-terminal domain of BRCA1.
J Comput Aided Mol Des. 2011 Nov;25(11):1071-84. doi: 10.1007/s10822-011-9484-3. Epub 2011 Nov 16.
引用本文的文献
1
Discovery and Validation of Lmj_04_BRCT Domain, a Novel Therapeutic Target: Identification of Candidate Drugs for Leishmaniasis.
Int J Mol Sci. 2021 Sep 28;22(19):10493. doi: 10.3390/ijms221910493.
2
Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy.
Bioorg Med Chem Lett. 2018 Dec 15;28(23-24):3736-3740. doi: 10.1016/j.bmcl.2018.10.020. Epub 2018 Oct 15.
3
Characterization of Promiscuous Binding of Phosphor Ligands to Breast-Cancer-Gene 1 (BRCA1) C-Terminal (BRCT): Molecular Dynamics, Free Energy, Entropy and Inhibitor Design.
PLoS Comput Biol. 2016 Aug 25;12(8):e1005057. doi: 10.1371/journal.pcbi.1005057. eCollection 2016 Aug.
4
Irreversible binding of an anticancer compound (BI-94) to plasma proteins.
Xenobiotica. 2015;45(10):858-73. doi: 10.3109/00498254.2015.1025250. Epub 2015 Apr 14.
5
Phosphopeptide interactions with BRCA1 BRCT domains: More than just a motif.
Prog Biophys Mol Biol. 2015 Mar;117(2-3):143-148. doi: 10.1016/j.pbiomolbio.2015.02.003. Epub 2015 Feb 17.
6
Peptide library approach to uncover phosphomimetic inhibitors of the BRCA1 C-terminal domain.
ACS Chem Biol. 2015 May 15;10(5):1198-208. doi: 10.1021/cb500757u. Epub 2015 Feb 5.
7
Small molecule adenosine 5'-monophosphate activated protein kinase (AMPK) modulators and human diseases.
J Med Chem. 2015 Jan 8;58(1):2-29. doi: 10.1021/jm401994c. Epub 2014 Aug 28.
8
The paradox of conformational constraint in the design of Cbl(TKB)-binding peptides.
Sci Rep. 2013;3:1639. doi: 10.1038/srep01639.
9
Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option.
Breast Cancer Res Treat. 2012 Jul;134(2):511-7. doi: 10.1007/s10549-012-2079-4. Epub 2012 May 6.
10
BRCA1-directed, enhanced and aberrant homologous recombination: mechanism and potential treatment strategies.
Cell Cycle. 2012 Feb 15;11(4):687-94. doi: 10.4161/cc.11.4.19212.
本文引用的文献
1
Comparison of the structures and peptide binding specificities of the BRCT domains of MDC1 and BRCA1.
Structure. 2010 Feb 10;18(2):167-76. doi: 10.1016/j.str.2009.12.008.
2
Structural characterization of BRCT-tetrapeptide binding interactions.
Biochem Biophys Res Commun. 2010 Mar 5;393(2):207-10. doi: 10.1016/j.bbrc.2010.01.098. Epub 2010 Feb 1.
3
BRCA1 and its toolbox for the maintenance of genome integrity.
Nat Rev Mol Cell Biol. 2010 Feb;11(2):138-48. doi: 10.1038/nrm2831. Epub 2009 Dec 23.
4
A thermodynamic approach to the affinity optimization of drug candidates.
Chem Biol Drug Des. 2009 Nov;74(5):468-72. doi: 10.1111/j.1747-0285.2009.00880.x. Epub 2009 Sep 28.
5
Small-molecule inhibitors of protein-protein interactions.
Curr Opin Drug Discov Devel. 2008 Sep;11(5):666-74.
6
Kinetic analysis of interaction of BRCA1 tandem breast cancer c-terminal domains with phosphorylated peptides reveals two binding conformations.
Biochemistry. 2008 Sep 16;47(37):9866-79. doi: 10.1021/bi702247d. Epub 2008 Aug 22.
7
Structural evidence for direct interactions between the BRCT domains of human BRCA1 and a phospho-peptide from human ACC1.
Biochemistry. 2008 May 27;47(21):5767-73. doi: 10.1021/bi800314m. Epub 2008 May 2.
8
Dual-fluorophore quantitative high-throughput screen for inhibitors of BRCT-phosphoprotein interaction.
Anal Biochem. 2008 Apr 1;375(1):60-70. doi: 10.1016/j.ab.2007.11.039. Epub 2007 Dec 5.
9
Thermodynamics of phosphopeptide tethering to BRCT: the structural minima for inhibitor design.
J Am Chem Soc. 2007 Sep 5;129(35):10658-9. doi: 10.1021/ja0739178. Epub 2007 Aug 9.
10
High-throughput fluorescence polarization assay to identify small molecule inhibitors of BRCT domains of breast cancer gene 1.
Anal Biochem. 2006 May 1;352(1):135-41. doi: 10.1016/j.ab.2006.01.025. Epub 2006 Feb 3.
Zotero 插件